CUSIP 16385C104SPONSORED ADSCMMBQ2 2025
17 filings · latest Aug 7, 2025
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Morgan Stanley | 1.61M | $1.87M |
| 2 | Orbimed Advisors LLC | 941.0K | $1.09M |
| 3 | Sphera Funds Management Ltd. | 738.0K | $856.1K |
| 4 | Yelin Lapidot Holdings Management Ltd. | 578.3K | $670.8K |
| 5 | Ikarian Capital, LLC | 213.1K | $247.1K |
| 6 | Rhumbline Advisers | 39.9K | $46.2K |
| 7 | Kestra Private Wealth Services, LLC | 31.2K | $36.2K |
| 8 | Boothbay Fund Management, LLC | 26.2K | $30.4K |
| 9 |
| 4 | Apr 10, 2025 | Sphera Funds Management Ltd. | 13G/A | 4.8% | 900.4K | SEC |
| 5 | Nov 29, 2024 | Mor George Adi | 13D/A | 4.8% | 898.2K | SEC |
| 6 | Nov 21, 2024 | Otto Erik | 13G | 6.1% | 1.16M | SEC |
| 7 | Sep 16, 2024 | Orbimed Israel Biofund Gp Limited Partnership | 13D/A | 10.0% | 1.86M | SEC |
| 8 | Aug 20, 2024 | Sphera Funds Management Ltd. | 13G | 6.6% | 1.21M | SEC |
| 9 | Mar 11, 2024 | Orbimed Israel Biofund Gp Limited Partnership | 13D/A | 16.0% | 2.27M | SEC |
| 10 | Nov 15, 2023 | Orbimed Israel Biofund Gp Limited Partnership | 13D/A | 18.3% | 2.27M | SEC |
See the full Schedule 13D/13G history for Chemomab Therapeutics Ltd.
Unlock full history| Jane Street Group, LLC |
| 20.6K |
| $23.9K |
| 10 | Bnp Paribas Financial Markets | 13.9K | $16.1K |